Project Grant R41AI195038
Award Date 9/11/25
Completion Date 8/31/26
Dollars Obligated $314K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Austin, TX 78750, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $676,666 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), for the project "Spatial and Temporal Adjuvant Delivery for Skin mRNA Vaccination". The goal of this project is to determine whether intranasal or intradermal delivery of a newly developed adjuvant can expand the breadth...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $299,968 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Viva Viral Vaccines, Inc. to develop a broad-spectrum, multivalent vaccine platform for pandemic and seasonal influenza. The platform leverages innovations in the production of influenza neuraminidase (NA) proteins in mammalian cells, enabling the development of VLP-based vaccines that can provide broad heterologous...
- This Project Grant award, totaling $390,942.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855). The goal of the project is to use self-assembled protein nanocages (SAPNs) as a universal flu vaccine platform to enhance the effectiveness of influenza vaccines. Specifically, the SAPNs will present multiple copies of three highly conserved influenza antigens: trimeric...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a broad-spectrum influenza vaccine. The project aims to evaluate recently discovered neuraminidase broadly neutralizing antibodies (NA BNAbs) and engineer NA immunogens that can engage diverse BNAb precursors, a strategy called germline targeting. This protein engineering effort...
- This $2,710,680 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to develop new generation mRNA-based vaccines for tuberculosis (TB). The goals are to: 1) develop mRNA vaccines expressing protective TB antigens combined with self-adjuvant peptides, 2) characterize the molecular mechanisms of the new mRNA vaccines, and 3) determine the efficacy of the vaccines against TB in mice....
- This Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000.00 in funding to Immuno Nano Med, Inc. to demonstrate the feasibility of producing a novel room-temperature-stable, dry-powder inhalable influenza vaccine. The goal is to develop an innovative, next-generation influenza vaccine technology that can promote public health by eliminating the pain points of current flu vaccines, such as the need...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,000,000 Project Grant to Partillion Bioscience Corp, a biotechnology company based in Los Angeles, California. The grant, funded under NIAID's Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of advanced workflows utilizing Partillion's specialized hydrogel microparticle technology called "nanovials". The goal is to enable ultra high-throughput screening and functional...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $292,746 Cooperative Agreement to Tsrl, Inc. (doing business as Therapeutic Systems Research Laboratories), a woman-owned small business located in Ann Arbor, Michigan. The purpose of this award is to conduct a Phase 1 clinical trial to assess the pharmacokinetics, safety, and tolerance of a zanamivir transdermal system in healthy subjects. This...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $308,669 Project Grant under the Allergy and Infectious Diseases Research Program (CFDA 93.855) to Vishenary, LLC to develop a novel vaccine with broad efficacy against nontypeable Haemophilus influenzae (NTHI) strains following influenza A virus (IAV) infection. The project aims to create a vaccine candidate consisting of a conserved NTHI protein (Protein 0259) and the FDA-approved histone deacetylase inhibitor...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $883,119 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute to develop a novel mRNA vaccine and immunotherapy against hepatitis B virus (HBV) infection. The award supports research to investigate viral and cellular factors that hinder effective antigen expression and improve vaccine antigens to elicit potent antibody and T cell responses to cure HBV...